Plague vaccine - PharmAthene

Drug Profile

Plague vaccine - PharmAthene

Alternative Names: Recombinant Yersinia pestis vaccine - PharmAthene; Recombinant dual antigen vaccine for plague - PharmAthene; rYP vaccine - PharmAthene; RypVax

Latest Information Update: 27 May 2010

Price : $50

At a glance

  • Originator Avecia
  • Developer PharmAthene
  • Class Plague vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Plague

Most Recent Events

  • 08 Oct 2004 Preclinical trials in Pneumonic plague in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top